- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Rhythm Pharmaceuticals Inc (RYTM)
The Rhythm Pharmaceuticals share price today is 110.68, view NASDAQ RYTM stock exchange data. Track the latest Rhythm Pharmaceuticals share price with real-time updates on RYTM stock performance including market cap, day range, 52-week range and dividend yield. Access RYTM charts, earnings dates and analyst estimates to support your investment decisions.
Currency in USD
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
85.04
110.68
52 wk Range
74.50
122.20
RYTM is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
85.04110.68
52 wk Range
74.50122.20
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
RYTM Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
140.29
Upside
+26.76%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Impressive gross profit margins
Rhythm Pharma receives Investment Bank Analyst Rating Update- Investing.com
Pro
- Rhythm Pharma receives Investment Bank Analyst Rating Update
- Investing.com
Pro 
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Buy
Moving Averages
Strong Buy
Analyst Ratings
17 Buy
2 Hold
0 Sell
Ratings:
19 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 140.29
(+26.76% Upside)
Rhythm Pharmaceuticals Inc Earnings Call Summary for Q3/2026
- Rhythm Pharmaceuticals beat Q3 2026 estimates with adjusted loss of $0.61/share vs. $0.71 expected; revenue hit $92.1M, up 29% sequentially.
- IMCIVREE global sales reached $92.1M driven by U.S. hypothalamic obesity launch; reimbursed patients increased 20% quarter-over-quarter.
- Company updated 2026 operating expense guidance to $360M-$380M; R&D midpoint reduced $15M due to timing shifts into early 2027.
- Phase III trial for bivamelagon in hypothalamic obesity to begin screening by year-end; Japan launch completed Oct. 14 with 1,000+ patients identified.
- Shares fell 4.22% premarket to $89.50 despite beat as investors weighed profitability timeline; company holds $321M cash, sufficient for 24+ months.
Last Updated: 03-11-2026, 07:48 pm
Read Full TranscriptEarnings
Latest Release
03-11-2026
EPS / Forecast
-0.61 / -0.71
Revenue / Forecast
92.1M / 85.44M
Compare RYTM to Peers and Sector
Metrics to compare | RYTM | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipRYTMPeersSector | |
|---|---|---|---|---|
P/E Ratio | −38.7x | −1.1x | −0.2x | |
PEG Ratio | −6.11 | −0.05 | 0.00 | |
Price/Book | 87.2x | 2.5x | 2.6x | |
Price / LTM Sales | 27.3x | 84.6x | 2.8x | |
Upside (Analyst Target) | 26.8% | 349.1% | 62.7% | |
Fair Value Upside | Unlock | 15.0% | 8.0% | Unlock |
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company’s lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syndrome, and hypothalamic obesity. It is in Phase 3 clinical trials for treating acquired hypothalamic obesity, congenital hypothalamic obesity, pro-opiomelanocortin (POMC) and LEPR insufficiency obesities, SRC1 deficiency obesity, and SH2B1 deficiency obesity; and in phase 2 clinical trails for the treatment of Prader-Willi syndrome and MC4R deficiency. The company is also developing bivamelagon, an investigational oral small molecule MC4R agonist that is in phase 2 clinical trial for the treatment of MC4R pathway diseases; and RM-718, a next generation MC4R peptide agonist that is in phase 1 clinical trial for the treatment of hypothalamic obesity. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Rhythm Pharmaceuticals (RYTM) Share Price Today?
The Rhythm Pharmaceuticals share price today is 110.68.
What is the current Rhythm Pharmaceuticals (RYTM) share price and day range?
As of 05-11-2026, the Rhythm Pharmaceuticals share price is 110.68, with a previous close of 86.44. The share price has ranged from 85.04 to 110.68 today, while the 52-week range spans from 74.50 to 122.20.
What Is the Rhythm Pharmaceuticals Market Cap?
As of today, Rhythm Pharmaceuticals market cap is 7.67B.
What Is the Rhythm Pharmaceuticals (RYTM) Share Price Target?
The average 12-month share price target for Rhythm Pharmaceuticals is 140.29, with a high estimate of 160 and a low estimate of 120. 17 analysts recommend buying, while 0 suggest selling, with an overall rating of Strong Buy and +26.76% Upside potential.
What Is Rhythm Pharmaceuticals's Earnings Per Share (TTM)?
The Rhythm Pharmaceuticals EPS (TTM) is -2.91.
When Is the Next Rhythm Pharmaceuticals Earnings Date?
Rhythm Pharmaceuticals will release its next earnings report on 03-03-2027.
From a Technical Analysis Perspective, Is RYTM a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
What Stock Exchange Does Rhythm Pharmaceuticals Trade On?
Rhythm Pharmaceuticals is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Rhythm Pharmaceuticals?
The stock symbol for Rhythm Pharmaceuticals is "RYTM."
How Many Times Has Rhythm Pharmaceuticals Stock Split?
Rhythm Pharmaceuticals has split 0 times.
How Many Employees Does Rhythm Pharmaceuticals Have?
Rhythm Pharmaceuticals has 414 employees.
What Is the RYTM Premarket Price?
RYTM's last pre-market stock price is 86.71. The pre-market share volume is 320.00, and the stock has changed by 0.27, or 0.31%.
What Is the RYTM After Hours Price?
RYTM's last after hours stock price is 109.75, the stock has changed by -0.93, or -0.84%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.